RxDoctor Payments Data

Barry Merrill, MD

Cardiovascular Disease · Boca Raton, FLNPI 1740265610

Payments from drug & device makers

$21,157in general payments, 2019–2025

Across 986 payments — averaging $21.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Novartis$2K
  • Johnson & Johnson$1K
  • Amgen$1K
  • Boehringer Ingelheim$1K
  • Abiomed$1K
  • plus $12K from 43 others

What the payments were for

  • Speaking & faculty fees$1251%
  • Food & beverage$21,00199%
  • Education$310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,157 in reported general payments places this provider in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$757,578
Medicare patients
1,648
Services billed
6,922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban335$336,402
XareltoRivaroxaban95$134,166
EntrestoSacubitril/Valsartan89$102,985
Repatha SureclickEvolocumab112$94,217
MultaqDronedarone Hcl67$87,696
JardianceEmpagliflozin81$79,338
FarxigaDapagliflozin Propanediol35$33,729
BrilintaTicagrelor28$23,532
OzempicSemaglutide14$13,344
VascepaIcosapent Ethyl24$11,644
Repatha PushtronexEvolocumab11$6,258
Metoprolol Succinate379$4,138
Rosuvastatin Calcium348$4,002
Nebivolol Hcl57$3,761
ClopidogrelClopidogrel Bisulfate249$2,977

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,297$336,402335 claims
Johnson & JohnsonXarelto$1,484$134,16695 claims
NovartisEntresto$1,792$102,98589 claims
Sanofi-aventis U.S. LLCMultaq$609$87,69667 claims
Boehringer IngelheimJardiance$1,386$79,33881 claims
AstraZenecaFarxiga, Brilinta$787$57,26263 claims
Novo NordiskOzempic$70$13,34414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →